Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Conference News ESC 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

Shelley Wood

September 01, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Presentation ESC 2024

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

Presenter: Pardeep S. Jhund

September 01, 2024

Presentation ESC 2024

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Presenter: Muthiah Vaduganathan

September 01, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

Todd Neale

September 01, 2024

News Conference News ESC 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

Shelley Wood

August 31, 2024

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

Todd Neale

August 31, 2024

Presentation ESC 2024

Transcatheter versus surgical mitral valve repair in patients with heart failure and secondary mitral regurgitation

Presenter: Volker Rudolph

August 31, 2024

Presentation ESC 2024

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

Presenter: Erwan Donal

August 31, 2024

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

L.A. McKeown

August 30, 2024

Advertisement

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

Transcatheter versus surgical mitral valve repair in patients with heart failure and secondary mitral regurgitation

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content